目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T28541 | |||
Ritipenem Acoxil is an antibiotics. | |||
T27962 | |||
LYS228 is a potent antibiotics against Carbapenem-Resistant Enterobacteriaceae (MIC90 = 2 uM/mL). LYS228 is potent in the presence of all classes of beta-lactamases. | |||
T24247 | |||
Kapurimycin A3 is an antitumor antibiotics. | |||
T26185 | |||
Septacidin represents a group of l-eptopyranoses including nucleoside antibiotics with antitumor, antifungal, and pain-relief activities. | |||
T25183 | |||
Bulgecin C is an O-sulfonated glycopeptides that can enhance the antibacterial activity of beta-lactam antibiotics. | |||
T23957 | |||
Dactylocyclines B is a novel tetracycline derivative produced by a Dactylosporangium sp. A screen for antibiotics with activity against tetracycline-resistant microorganisms has led to the isolation of Dactylosporangium sp. | |||
T26465 | |||
A1-226 is a cephalosporin of the class of β-lactam antibiotics, it is originally derived from the fungus Acremonium. | |||
T28436 | |||
Polyoxin B is a nucleoside antibiotics composed of heterocyclic moieties containing nitrogen. Polyoxin B inhibits the biosynthesis of chitin. | |||
T23952L | |||
Dactimicin is a new aminoglycoside. It also has in vitro activity, post-antibiotic effect, and interaction with other antibiotics. | |||
TN4319 | Antifection | ||
Isopimaric acid is active against MDR and MRSA strains of S. aureus which are becoming increasingly resistant to antibiotics, the minimum inhibitory concentrations (MIC) are 32-64 microg/mL . Isopimaric acid is also possible that an antagonistic interacti |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPH-02373 | Metallo-beta-lactamase type 2 Protein, Klebsiella pneumoniae, Recombinant (His) | Klebsiella pneumoniae | E. coli | ||
Confers resistance to the different beta-lactams antibiotics (penicillin, cephalosporin and carbapenem) via the hydrolysis of the beta-lactam ring. Does not confer resistance to the polymixin colistin or the fluoroquinolone ciprofloxacin.
|
|||||
TMPH-03488 | Metallo-beta-lactamase type 2 Protein, Serratia marcescens, Recombinant (His & Myc) | Serratia marcescens | E. coli | ||
Confers resistance to the different beta-lactams antibiotics (penicillin, cephalosporin and carbapenem) via the hydrolysis of the beta-lactam ring. Metallo-beta-lactamase type 2 Protein, Serratia marcescens, Recombinant (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 32.6 kDa and the accession number is P52699.
|
|||||
TMPH-00587 | Beta-lactamase TEM Protein, E. coli, Recombinant (His & SUMO) | E. coli | E. coli | ||
TEM-type are the most prevalent beta-lactamases in enterobacteria; they hydrolyze the beta-lactam bond in susceptible beta-lactam antibiotics, thus conferring resistance to penicillins and cephalosporins. TEM-3 and TEM-4 are capable of hydrolyzing cefotaxime and ceftazidime. TEM-5 is capable of hydrolyzing ceftazidime. TEM-6 is capable of hydrolyzing ceftazidime and aztreonam. TEM-8/CAZ-2, TEM-16/CAZ-7 and TEM-24/CAZ-6 are markedly active against ceftazidime. IRT-4 shows resistance to beta-lactamase inhibitors.
|
|||||
TMPH-00586 | Beta-lactamase TEM Protein, E. coli, Recombinant (His) | E. coli | P. pastoris (Yeast) | ||
TEM-type are the most prevalent beta-lactamases in enterobacteria; they hydrolyze the beta-lactam bond in susceptible beta-lactam antibiotics, thus conferring resistance to penicillins and cephalosporins. TEM-3 and TEM-4 are capable of hydrolyzing cefotaxime and ceftazidime. TEM-5 is capable of hydrolyzing ceftazidime. TEM-6 is capable of hydrolyzing ceftazidime and aztreonam. TEM-8/CAZ-2, TEM-16/CAZ-7 and TEM-24/CAZ-6 are markedly active against ceftazidime. IRT-4 shows resistance to beta-lactamase inhibitors.
|
|||||
TMPY-01812 | Enoyl-ACP Reductase Protein, E. coli, Recombinant (His) | E. coli | E. coli | ||
Enoyl-ACP reductase, also known as NADH-dependent enoyl-ACP reductase and FABI, is a cell inner membrane and peripheral membrane protein which belongs to theshort-chain dehydrogenases/reductases (SDR) family and FabI subfamily. Microorganisms produce many kinds of antibiotics which function in an antagonistic capacity in nature where they have much competition. Bacterial FAS provides essential fatty acids for use in the assembly of key cellular components. Among them, FABI is an enoyl-ACP reductase which catalyzes the final and rate-limiting step of bacterial FAS. The antibiotic diazaborine interferes with the activity by binding to the protein. FABI is a potential target for selective antibacterial action, because it shows low overall sequence homology with mammalian enzymes. Various compounds have been reported as inhibitors of bacterial FabI-inhibitory compounds.
|